<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742001</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-0040</org_study_id>
    <nct_id>NCT00742001</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>IMPROVE: Inactivation of Whole Blood With Mirasol (R): Performance in Red Blood Cells, Platelets and Plasma Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCTbio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Terumo BCTbio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility trial to evaluate recovery and survival of RBCs from Mirasol-treated whole blood
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiolabeling of red blood cells with subsequent autologous infusion of the donor is commonly
      used as a surrogate to evaluate circulation of red blood cells in vivo. By measuring the
      level of radioisotope in a blood sample, these tests evaluate what percentage of the red
      blood cells remain in the bloodstream after 24 hours (recovery) and can predict how long the
      red blood cells will remain in circulation (survival). The IMPROVE trial is a feasibility
      trial to evaluate these parameters in red blood cells obtained from whole blood units that
      have been treated with the Mirasol System.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    An endpoint difference between 3 energies was not observed. Correlations between recovery and
    ATP were established, and will be used for a Whole Blood system.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC recovery</measure>
    <time_frame>24 hr post autologous infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC survival</measure>
    <time_frame>28 days post autologous infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>post autologous infusion of RBC</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole blood units treated with Mirasol at Illumination dose #1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Blood units treated with Mirasol at Illumination dose #2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Blood units treated with Mirasol at Illumination dose #3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mirasol System for Whole Blood.</intervention_name>
    <description>Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
    <arm_group_label>Mirasol Illumination Dose #1</arm_group_label>
    <arm_group_label>Mirasol Illumination Dose #2</arm_group_label>
    <arm_group_label>Mirasol Illumination Dose #3</arm_group_label>
    <other_name>Mirasol System</other_name>
    <other_name>Mirasol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults who meet AABB criteria for whole blood donation

          -  females incapable of becoming pregnant

          -  males agreeing to use contraception during trial

        Exclusion Criteria:

          -  pregnancy or nursing

          -  abnormal medical history (bleeding disorders, anemia, MI, uncontrolled hypertension,
             heart disease, epilepsy)

          -  major surgery

          -  use of drugs affecting coagulation or RBC function

          -  recent participation in other trials which may confound results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Cancelas-Perez, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati, Hoxworth Blood Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati, Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director of Regulatory and Clinical Affairs</name_title>
    <organization>CaridianBCT Biotechnologies (formerly Navigant Biotechnologies)</organization>
  </responsible_party>
  <keyword>red blood cells</keyword>
  <keyword>transfusion</keyword>
  <keyword>recovery</keyword>
  <keyword>feasibility</keyword>
  <keyword>white blood cell inactivation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

